Published in Agents Actions Suppl on January 01, 1991
Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes. J Virol (1992) 5.85
Autoregulation of Th1-mediated inflammation by twist1. J Exp Med (2008) 1.43
The effect of anti-CD4 on helper function of CD4,45RA+ versus CD4,45RO+ T cells. Clin Exp Immunol (1994) 0.77
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med (2000) 16.20
Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum (1998) 8.69
Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet (1994) 7.04
Immunosuppressive effects of apoptotic cells. Nature (1997) 7.03
Improvement of PCR amplified DNA sequencing with the aid of detergents. Nucleic Acids Res (1990) 5.13
A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) (2003) 4.86
Soluble CD4 molecules neutralize human immunodeficiency virus type 1. Nature (1988) 3.63
Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Ann Rheum Dis (2002) 3.53
Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus. Arthritis Rheum (1998) 3.41
Range of antinuclear antibodies in "healthy" individuals. Arthritis Rheum (1997) 3.29
Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum (2004) 3.00
A rapid and simple method for the isolation of apoptotic DNA fragments. Nucleic Acids Res (1994) 2.96
European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis (2011) 2.74
Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol (1999) 2.74
Autoantibody profiles in the sera of European patients with myositis. Ann Rheum Dis (2001) 2.69
EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees. Ann Rheum Dis (2004) 2.48
Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. Ann Rheum Dis (2008) 2.45
Cloning of a novel family of mammalian GTP-binding proteins (RagA, RagBs, RagB1) with remote similarity to the Ras-related GTPases. J Biol Chem (1995) 2.41
The kinase DYRK1A phosphorylates the transcription factor FKHR at Ser329 in vitro, a novel in vivo phosphorylation site. Biochem J (2001) 2.36
The EPIC nutrient database project (ENDB): a first attempt to standardize nutrient databases across the 10 European countries participating in the EPIC study. Eur J Clin Nutr (2007) 2.21
Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial. Arthritis Rheum (2003) 2.20
The identification of leaf thionin as one of the main jasmonate-induced proteins of barley (Hordeum vulgare). Plant Mol Biol (1992) 2.08
An analysis of the saccadic system by means of double step stimuli. Vision Res (1979) 2.07
Specificity determinants of substrate recognition by the protein kinase DYRK1A. J Biol Chem (2000) 2.05
Dyrk, a dual specificity protein kinase with unique structural features whose activity is dependent on tyrosine residues between subdomains VII and VIII. J Biol Chem (1996) 2.00
Antibodies to simian T-lymphotropic retrovirus type III in African green monkeys and recognition of STLV-III viral proteins by AIDS and related sera. Lancet (1985) 1.96
In vitro apoptosis and expression of apoptosis-related molecules in lymphocytes from patients with systemic lupus erythematosus and other autoimmune diseases. Arthritis Rheum (1997) 1.95
Disseminated thyroid autonomy or Graves' disease: reevaluation by a second generation TSH receptor antibody assay. Thyroid (2000) 1.95
Human herpesvirus type 8 interleukin-6 homologue is functionally active on human myeloma cells. Blood (1998) 1.93
[German 2012 guidelines for the sequential medical treatment of rheumatoid arthritis. Adapted EULAR recommendations and updated treatment algorithm]. Z Rheumatol (2012) 1.91
Activated T cells in vivo and in vitro: divergence in expression of Tac and Ia antigens in the nonblastoid small T cells of inflammation and normal T cells activated in vitro. J Immunol (1984) 1.87
Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomised controlled trial. Ann Rheum Dis (2006) 1.86
A critical evaluation of enzyme immunoassays for detection of antinuclear autoantibodies of defined specificities. I. Precision, sensitivity, and specificity. Arthritis Rheum (1999) 1.85
Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years. Rheumatology (Oxford) (2005) 1.82
Analysis of the systemic and intrathecal humoral immune response in progressive multifocal leukoencephalopathy. J Infect Dis (1997) 1.79
Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine. Ann Rheum Dis (2001) 1.78
Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. Ann Rheum Dis (2005) 1.77
Value of F-18 FDG hybrid camera PET and MRI in early takayasu aortitis. Eur Radiol (2002) 1.76
Atypical X-linked severe combined immunodeficiency due to possible spontaneous reversion of the genetic defect in T cells. N Engl J Med (1996) 1.73
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis (2007) 1.70
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011. Ann Rheum Dis (2012) 1.67
Joint and connective tissue ultrasonography--a rheumatologic bedside procedure? A German experience. Arthritis Rheum (1995) 1.66
Prediction in the oculomotor system: smooth pursuit during transient disappearance of a visual target. Exp Brain Res (1985) 1.66
Evidence-based, interdisciplinary guidelines for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis. Rheumatol Int (2011) 1.64
Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study. Ann Rheum Dis (2003) 1.64
Human IgG anti-DNA antibodies deposit in kidneys and induce proteinuria in SCID mice. Kidney Int (1995) 1.63
Successful treatment of a small cohort of patients with adult onset of Still's disease with infliximab: first experiences. Ann Rheum Dis (2001) 1.63
The balance of Th1/Th2 cytokines in rheumatoid arthritis. Best Pract Res Clin Rheumatol (2001) 1.62
Identification of the autophosphorylation sites and characterization of their effects in the protein kinase DYRK1A. Biochem J (2001) 1.61
SLE--a disease of clearance deficiency? Rheumatology (Oxford) (2005) 1.59
Towards metabolic mapping of the human retina. Microsc Res Tech (2007) 1.55
Faecal alpha-1-antitrypsin and excretion of 111indium granulocytes in assessment of disease activity in chronic inflammatory bowel diseases. Gut (1987) 1.54
Single-photon-emission computed tomography analysis of cerebral blood flow in the evaluation of central nervous system involvement in patients with systemic lupus erythematosus. Arthritis Rheum (1993) 1.53
Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Ann Rheum Dis (2004) 1.53
Effects of IFN on human eosinophils in comparison with other cytokines. A novel class of eosinophil activators with delayed onset of action. J Immunol (1990) 1.52
Studies on experimental autoimmune thymitis in guinea-pigs. Clin Exp Immunol (1969) 1.50
Analysis of immunoglobulin variable region genes from human IgG anti-DNA hybridomas. Eur J Immunol (1992) 1.48
In vitro and in vivo effect of glucocorticoids on IgE and IgG subclass secretion. Clin Exp Allergy (1994) 1.47
Infliximab in active early rheumatoid arthritis. Ann Rheum Dis (2004) 1.47
Proximal tubular epithelial hyperplasia in patients with chronic glomerular proteinuria. Kidney Int (2000) 1.46
Differential inhibitory effects of intravenous immunoglobulin preparations on HLA-alloantibodies in vitro. Transplantation (2001) 1.46
Treatment of rheumatoid arthritis with an anti-CD4 monoclonal antibody. Arthritis Rheum (1991) 1.45
Intake of fatty acids in western Europe with emphasis on trans fatty acids: the TRANSFAIR Study. Eur J Clin Nutr (1999) 1.45
Cardiac death after autologous stem cell transplantation (ASCT) for treatment of systemic sclerosis (SSc): no evidence for cyclophosphamide-induced cardiomyopathy. Bone Marrow Transplant (2001) 1.44
EULAR report on the use of ultrasonography in painful knee osteoarthritis. Part 1: prevalence of inflammation in osteoarthritis. Ann Rheum Dis (2005) 1.44
CD4 positive peripheral T cells from patients with systemic lupus erythematosus (SLE) are clonally expanded. Lupus (2001) 1.44
Methyl mercury and inorganic mercury in Swedish pregnant women and in cord blood: influence of fish consumption. Environ Health Perspect (2003) 1.43
Further properties of the human saccadic system: eye movements and correction saccades with and without visual fixation points. Vision Res (1969) 1.43
Serum concentrations of organochlorines in men: a search for markers of exposure. Sci Total Environ (2000) 1.40
[Cartilage-specific autoimmunity in otosclerosis]. HNO (1993) 1.40
Influences on food choice perceived to be important by nationally-representative samples of adults in the European Union. Eur J Clin Nutr (1997) 1.39
Definition of risk factors for death, end stage renal disease, and thromboembolic events in a monocentric cohort of 338 patients with systemic lupus erythematosus. Ann Rheum Dis (2002) 1.39
[On the temporal disintegration of mono- and binaural intensity differences (sounds and white background noise)]. Arch Klin Exp Ohren Nasen Kehlkopfheilkd (1967) 1.38
[Neonatal hyperthyroidism in non-diagnosed Basedow's disease of the mother. Problems of diagnosis and therapy illustrated by a case history]. Dtsch Med Wochenschr (1994) 1.37
Cellular and humoral immune response in progressive multifocal leukoencephalopathy. Ann Neurol (2001) 1.35
Dietary intake estimations of organohalogen contaminants (dioxins, PCB, PBDE and chlorinated pesticides, e.g. DDT) based on Swedish market basket data. Food Chem Toxicol (2006) 1.35
Determination of antisera titres ing the single radial immunodiffusion method. Immunochemistry (1969) 1.35
Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations. Eur J Nucl Med (1998) 1.34
Diversity, functionality, and stability of the T cell repertoire derived in vivo from a single human T cell precursor. Proc Natl Acad Sci U S A (2000) 1.34
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009. Ann Rheum Dis (2010) 1.34
Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002). Ann Rheum Dis (2002) 1.33
Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomised controlled trials of two tumour necrosis factor inhibitors. Ann Rheum Dis (2006) 1.32
Estimating the distribution of usual dietary intake by short-term measurements. Eur J Clin Nutr (2002) 1.32
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Ann Rheum Dis (2008) 1.31
Natural and drug-induced variations of velocity and duration of human saccadic eye movements: evidence for a control of the neural pulse generator by local feedback. Biol Cybern (1981) 1.31
Clearance of apoptotic cells in human SLE. Curr Dir Autoimmun (2006) 1.29
Persistence of Borrelia burgdorferi in ligamentous tissue from a patient with chronic Lyme borreliosis. Arthritis Rheum (1993) 1.27
[Structural quality of rheumatology clinics for children and adolescents. Paper by a task force of the "Society of Pediatric and Adolescent Rheumatology" and of the "Association of Rheumatology Clinics in Germany"]. Z Rheumatol (2006) 1.27
Breast thermography after four years and 10000 studies. Am J Roentgenol Radium Ther Nucl Med (1972) 1.27
Etiopathogenesis of systemic lupus erythematosus. Immunol Today (2000) 1.26
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006. Ann Rheum Dis (2006) 1.25
Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003). Ann Rheum Dis (2003) 1.25
A consensus protocol for white blood cells labelling with technetium-99m hexamethylpropylene amine oxime. International Society of Radiolabeled Blood Elements (ISORBE) Eur J Nucl Med (1998) 1.25
The MNB/DYRK1A protein kinase: neurobiological functions and Down syndrome implications. J Neural Transm Suppl (2003) 1.25